Biopharma

Chutes & Ladders—J&J innovator vaults to Valo

After more than 13 years at Johnson & Johnson, including most recently serving a...

PSUSA/00000742/202408

PSUSA/00000742/202408

PSUSA/00000986/202409

PSUSA/00000986/202409

Time runs out for Kronos’ headquarters amid wider cost-...

Kronos Bio is vacating its corporate headquarters in California amid a wider cos...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Kisunla, donanemab, St...

Meeting highlights from the Pharmacovigilance Risk Asse...

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Fingolimod Accord, fin...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Sialanar, glycopyrroni...

Emergency Task Force (ETF)

Emergency Task Force (ETF)

Composition of the Emergency Task Force (ETF) for prepa...

Composition of the Emergency Task Force (ETF) for preparedness

Superseded - Composition of the Emergency Task Force (E...

Superseded - Composition of the Emergency Task Force (ETF) for preparedness

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Orphacol, cholic acid,...

CHMP-CAT - D80-210 Overview to final EPAR - Rev 04.25 (...

CHMP-CAT - D80-210 Overview to final EPAR - Rev 04.25 (Revamp)

Rules of procedure of the Emergency Task Force (ETF)

Rules of procedure of the Emergency Task Force (ETF)

Superseded - Rules of procedure of the Emergency Task F...

Superseded - Rules of procedure of the Emergency Task Force (ETF)

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Revestive, teduglutide...

Opinion: Other countries must step up to fill the void ...

Foreign assistance offers collective benefit — to security interests, humanitari...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Moventig, naloxegol, D...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagen...

Swiss drugmaker Novartis to invest $23bn in US manufact...

Pharma group builds out American supply chains as part of preparations for poten...

All-Cause Mortality Increased From 2020 to 2021 Nationwide

THURSDAY, April 10, 2025 -- All-cause mortality increased in 2020 to 2021 natio...

Icotrokinra Results Show 75% of Adolescents with Plaque...

SPRING HOUSE, Pa. (April 10, 2025) – Johnson & Johnson (NYSE: JNJ) today announc...

Tolebrutinib Phase 3 Data Published in NEJM Demonstrate...

Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published posit...

Amid tariff turmoil, Novartis commits to spending $23B ...

Novartis expects the new capacity will allow it to produce all of its key medici...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.